ASHPOfficial

The use of biotherapies has surged in recent years, creating new challenges and opportunities for pharmacy. In this episode, three experienced pharmacists in the world of biotherapeutic drugs will review key considerations for working with these agents. Their discussion will cover biosafety review processes and how to develop the structure to support ongoing management of biotherapeutics.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast describes a research project at an academic health system to pilot an outpatient pharmacy continuous glucose monitoring service. Listeners will learn about the process of developing and implementing a continuous glucose monitoring service within an outpatient pharmacy setting. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode discusses the urgency for pharmacists to transition from using Cockcroft-Gault eCrCL to non-race based estimated glomerular filtration rate (eGFR) to improve medication-related decision-making in persons with reduced kidney function.  Listeners will learn how to transition from C-G eCrCL to eGFR adjusted for body surface area to improve medication effectiveness and safety in persons with chronic kidney disease.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Two wellness experts discuss ways that we can take care of our own well-being. They will share insights into how events in our workday interfere with wellness and what we can do to maintain and re-establish wellness. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast explores the growing concern of muscle loss associated with GLP-1 receptor agonist therapy for obesity management. It highlights the need for greater awareness among clinicians and patients, emphasizing strategies such as adequate protein intake, strength training, and emerging pharmacologic options to preserve muscle mass. The discussion underscores the importance of muscle preservation for long-term health and quality of life in individuals using GLP-1 therapies.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.